Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease.



Status:Archived
Conditions:High Blood Pressure (Hypertension), Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:Cardiology / Vascular Diseases, Nephrology / Urology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:March 2011
End Date:January 2013

Use our guide to learn which trials are right for you!

A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate Renal Impairment


The purpose of this study is to evaluate long term safety and tolerability of azilsartan
medoxomil and chlorthalidone, once daily (QD), compared with olmesartan medoxomil and
hydrochlorothiazide in hypertensive participants with moderate renal impairment.


A major component of blood pressure regulation is the renin-angiotensin-aldosterone system
(RAAS). Drugs that modulate the RAAS are used commonly worldwide for the treatment of
hypertension. TAK-491 (azilsartan medoxomil) is a prodrug of TAK-536 (azilsartan), an
angiotensin II receptor blocker (ARB). Azilsartan medoxomil is being evaluated by Takeda to
treat participants with essential hypertension.

Chlorthalidone is an orally administered thiazide-type diuretic agent, and some long-term
outcomes trials show blood pressure reductions associated with chlorthalidone treatment
reduce risk of cardiovascular morbidity and mortality.

Hypertensive patients with moderate renal impairment are a relatively more severe and
resistant hypertension population, and may benefit from effective fixed-dose combination
treatments such as an ARB plus a thiazide-type diuretic for blood pressure control.

Participants will be randomized to receive azilsartan medoxomil and chlorthalidone or
olmesartan medoxomil and hydrochlorothiazide for up to 52 weeks to evaluate long term safety
of azilsartan medoxomil and chlorthalidone. A titration-to-target blood pressure approach
will be used to guide the titration of study medication in this trial.


We found this trial at
15
sites
Austin, Texas
?
mi
from
Austin, TX
Click here to add this to my saved trials
Albany, New York
?
mi
from
Albany, NY
Click here to add this to my saved trials
Atlanta, Georgia
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1351 Kimberly Rd
Bettendorf, Iowa 52722
(563) 355-7733
Hematology Oncology Associates of the Quad Cities
?
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Birmingham, Alabama
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Celebration, Florida
?
mi
from
Celebration, FL
Click here to add this to my saved trials
Charlotte, North Carolina
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
?
mi
from
Lima, OH
Click here to add this to my saved trials
Louisville, Kentucky
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Mountlake Terrace, Washington
?
mi
from
Mountlake Terrace, WA
Click here to add this to my saved trials
Nashville, Tennessee
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Newington, Connecticut
?
mi
from
Newington, CT
Click here to add this to my saved trials
Peoria, Arizona
?
mi
from
Peoria, AZ
Click here to add this to my saved trials
Philadelphia, Pennsylvania
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Santa Clara, California 95051
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials